Appetite stimulants for patients with cancer: current evidence for clinical practice.
Nutr Rev
; 80(4): 857-873, 2022 03 10.
Article
em En
| MEDLINE
| ID: mdl-34389868
The incidence of neoplastic diseases has increased worldwide, with an estimated global burden of 19.3 million incident cases and 10 million deaths in 2020-a considerable increase compared with 9.6 million deaths in 2018. One of the most prevalent problems faced by patients with cancer and their physicians is malnutrition. It is estimated that patients with cancer have important nutritional alterations in 25% to 70% of cases, which directly affects many spheres of patient care and well-being, including quality of life, treatment toxicity, and survival outcomes. Despite the overwhelming need to address this pressing issue, current evidence in terms of pharmacologic interventions for cancer-related anorexia remains inconclusive, and there is no current standard of care for patients with cancer-related anorexia. Nonetheless, international guidelines recommend promoting anabolism through nutritional, physical, and pharmacologic therapies. In this review, the available information is summarized regarding pharmacologic therapies to treat cancer-related anorexia and findings are highlighted from a clinical stance.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Desnutrição
/
Neoplasias
Tipo de estudo:
Etiology_studies
/
Guideline
Aspecto:
Determinantes_sociais_saude
/
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
Nutr Rev
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
México
País de publicação:
Estados Unidos